CRIS 100
Alternative Names: CRIS-100Latest Information Update: 03 Mar 2023
At a glance
- Originator Cristalia
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spinal cord injuries
Most Recent Events
- 28 Feb 2023 Cristalia plans a phase I trial for Spinal cord injuries (In adults, In the elderly) in unknown location (NCT05739734)
- 22 Feb 2023 Preclinical trials in Spinal cord injuries in Brazil (Intraspinal) prior to February 2023